Literature DB >> 12351590

Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!

David S Alberts, Maurie Markman, Deborah Armstrong, Mace L Rothenberg, Franco Muggia, Stephen B Howell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12351590     DOI： 10.1200/JCO.2002.20.19.3944

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

Review 1.  Intraperitoneal chemotherapy for ovarian cancer.

Authors:  Gregory Friberg; Gini Fleming
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

2.  Intraperitoneal chemotherapy for epithelial ovarian cancer - single center experience.

Authors:  Rajshekhar C Jaka; S P Somashekhar; Shabber S Zaveri; Zahoor Ahmed; K R Ashwin
Journal:  Indian J Surg Oncol       Date:  2012-07-04

Review 3.  Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy.

Authors:  Robert L Coleman; Anil K Sood
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

4.  A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.

Authors:  Meiqin Yuan; Zeng Wang; Guinv Hu; Yunshan Yang; Wangxia Lv; Fangxiao Lu; Haijun Zhong
Journal:  Mol Clin Oncol       Date:  2016-06-02

5.  Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.

Authors:  Francesca Casagrande; Emiliano Cocco; Stefania Bellone; Christine E Richter; Marta Bellone; Paola Todeschini; Eric Siegel; Joyce Varughese; Dan Arin-Silasi; Masoud Azodi; Thomas J Rutherford; Sergio Pecorelli; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2011-06-20       Impact factor: 6.860

6.  Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.

Authors:  C F Verschraegen; S Kumagai; R Davidson; B Feig; P Mansfield; S J Lee; D S Maclean; W Hu; A R Khokhar; Z H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-29       Impact factor: 4.553

7.  Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.

Authors:  D S Alberts; M Markman; F Muggia; R F Ozols; E Eldermire; M A Bookman; T Chen; J Curtin; L M Hess; L Liebes; R C Young; E Trimble
Journal:  Gynecol Oncol       Date:  2006-10-27       Impact factor: 5.482

Review 8.  Systems pathology--taking molecular pathology into a new dimension.

Authors:  Dana Faratian; Robert G Clyde; John W Crawford; David J Harrison
Journal:  Nat Rev Clin Oncol       Date:  2009-07-07       Impact factor: 66.675

Review 9.  Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.

Authors:  P A Vasey
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

Review 10.  Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy.

Authors:  Diana P English; Alessandro D Santin
Journal:  Int J Mol Sci       Date:  2013-05-17       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.